Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calcium Electroporation for Head and Neck Cancer
NCT03051269Phase 1Unknown
- Sponsor
- Rigshospitalet
- Start
- May 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of calcium chloride in head and neck cancer (HNC), sponsored by Rigshospitalet. Primary endpoints: Change in Treatment-Emergent Adverse Events at 2 months and Change in Blood Calcium Levels at Day 3. Status: unknown.
02
Drugs
calcium chloride
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT03051269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03051269.